Cardiovascular biomarkers in chronic kidney disease: State of current research and clinical applicability

Disease Markers

Volumn 2015, Issue , 2015, Pages

  D'Marco, Luis ^a   Bellasi, Antonio ^b,c   Raggi, Paolo ^d,e  

^a Unidad Avanzada de Investigación y Diagnostico Ecográfico y Renal   (Venezuela)

^b SANT ANNA HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF ALBERTA   (Canada)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIPROTEIN PARTICLE; CARDIAC TROPONIN T; FETUIN A; FIBROBLAST GROWTH FACTOR 23; GROWTH DIFFERENTIATION FACTOR 15; KLOTHO PROTEIN; LEPTIN; N(G),N(G) DIMETHYLARGININE; NATRIURETIC FACTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TROPONIN T; UNCLASSIFIED DRUG; WNT PROTEIN; PLASMA PROTEIN;

ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; HIGH RISK PATIENT; HUMAN; LABORATORY DIAGNOSIS; NEPHROLOGY; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; REPRODUCIBILITY; RISK ASSESSMENT; STANDARDIZATION; UREMIA; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; VALIDATION STUDY;

ANIMALS; BIOMARKERS; BLOOD PROTEINS; CARDIOVASCULAR DISEASES; HUMANS; RENAL INSUFFICIENCY, CHRONIC; VALIDATION STUDIES AS TOPIC;

EID: 84928473069     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/586569     Document Type: Article

References (165)

1. E. L. Schiffrin, M. L. Lipman, and J. F. E. Mann, "Chronic kidney disease: effects on the cardiovascular system, " Circulation, vol. 116, no. 1, pp. 85-97, 2007.
2. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-Y. Hsu, "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, " The New England Journal of Medicine, vol. 351, no. 13, pp. 1296-1305, 2004.
3. S. Vickery, M. C. Webb, C. P. Price, R. I. John, N. A. Abbas, and E. J. Lamb, "Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population, " Nephrology Dialysis Transplantation, vol. 23, no. 11, pp. 3546-3553, 2008.
4. R. G. Fassett, S. K. Venuthurupalli, G. C. Gobe, J. S. Coombes, M. A. Cooper, and W. E. Hoy, "Biomarkers in chronic kidney disease: a review, " Kidney International, vol. 80, no. 8, pp. 806-821, 2011.
5. Y. Iwanaga and S. Miyazaki, "Heart failure, chronic kidney disease, and biomarkers-an integrated viewpoint, " Circulation Journal, vol. 74, no. 7, pp. 1274-1282, 2010.
6. Y. Iwanaga, I. Nishi, S. Furuichi et al. , "B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure, " Journal of theAmericanCollege of Cardiology, vol. 47, no. 4, pp. 742-748, 2006.
7. P. A. McCullough, R. M. Nowak, J. McCord et al. , "B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study, " Circulation, vol. 106, no. 4, pp. 416-422, 2002.
8. V. Epshteyn, K. Morrison, P. Krishnaswamy et al. , "Utility of Btype natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes, " Diabetes Care, vol. 26, no. 7, pp. 2081-2087, 2003.
9. A. S. Maisel, P. Krishnaswamy, R. M. Nowak et al. , "Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure, "TheNew England Journal ofMedicine, vol. 347, no. 3, pp. 161-167, 2002.
10. R. Xu, P. Ye, L. Luo et al. , "Association between high-sensitivity cardiac troponin T and N-terminal pro-brain natriuretic peptide in a community based population, " Chinese Medical Journal, vol. 127, no. 4, pp. 638-644, 2014.
11. K. Kara, A. A. Mahabadi, M. H. Geisel et al. , "B-type natriuretic peptide: distribution in the general population and the association withmajor cardiovascular and coronary events-theHeinz Nixdorf Recall Study, " Clinical Research in Cardiology, vol. 103, no. 2, pp. 125-132, 2014.
12. K. Kara, N. Lehmann, T. Neumann et al. , "NT-proBNP is superior to BNP for predicting first cardiovascular events in the general population: the Heinz Nixdorf Recall Study, " International Journal of Cardiology, vol. 183, pp. 155-161, 2015.
13. Z. Hijazi, J. Oldgren, U. Andersson et al. , "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy, " Circulation, vol. 125, no. 13, pp. 1605-1616, 2012.
14. H. G. Wahl, S. Graf, H. Renz, and W. Fassbinder, "Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis, " Clinical Chemistry, vol. 50, no. 6, pp. 1071-1074, 2004.
15. Y. Ishizaka, Y. Yamamoto, M. Tanaka et al. , "Molecular forms of human brain natriuretic peptide (BNP) in plasma of patients on hemodialysis (HD), " Clinical Nephrology, vol. 43, no. 4, pp. 237-242, 1995.
16. P. A. McCullough, T. Omland, and A. S. Maisel, "B-type natriuretic peptides: a diagnostic breakthrough for clinicians, " Reviews in Cardiovascular Medicine, vol. 4, no. 2, pp. 72-80, 2003.
17. S. Niizuma, Y. Iwanaga, T. Yahata et al. , "Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and endstage renal disease, " Clinical Chemistry, vol. 55, no. 7, pp. 1347-1353, 2009.
18. F. S. Apple, M. A. M. Murakami, L. A. Pearce, and C. A. Herzog, "Multi-biomarker risk stratification ofN-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for allcause death, " Clinical Chemistry, vol. 50, no. 12, pp. 2279-2285, 2004.
19. C. R. DeFilippi, S. L. Seliger, S. Maynard, and R. H. Christenson, "Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality, " Clinical Chemistry, vol. 53, no. 8, pp. 1511-1519, 2007.
20. M. Sakuma, M. Nakamura, F. Tanaka et al. , "Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population, " Circulation Journal, vol. 74, no. 4, pp. 792-797, 2010.
21. C. Sommerer, J. Beimler, V. Schwenger et al. , "Cardiac biomarkers and survival in haemodialysis patients, " European Journal of Clinical Investigation, vol. 37, no. 5, pp. 350-356, 2007.
22. A. Y.-M. Wang, C. W.-K. Lam, C.-M. Yu et al. , "N-terminal probrain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients, " Journal of the American Society of Nephrology, vol. 18, no. 1, pp. 321-330, 2007.
23. R. Paniagua, M.-D. Ventura, M. Avila-Dáz et al. , "NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients, " Nephrology Dialysis Transplantation, vol. 25, no. 2, pp. 551-557, 2010.
24. M. Svensson, A. Gorst-Rasmussen, E. B. Schmidt, K. A. Jorgensen, and J. H. Christensen, "NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease, " Clinical Nephrology, vol. 71, no. 4, pp. 380-386, 2009.
25. A. S. Jaffe, L. Babuin, and F. S. Apple, "Biomarkers in acute cardiac disease: the present and the future, " Journal of the American College of Cardiology, vol. 48, no. 1, pp. 1-11, 2006.
26. S. Kiatchoosakun, D. Sahasthas, C. Wongvipaporn, and C. Pongskul, "Cardiac troponin-T in pre-end stage kidney disease, " Journal of the Medical Association ofThailand, vol. 91, no. 12, pp. 1806-1811, 2008.
27. C. Sommerer, E. Giannitsis, V. Schwenger, and M. Zeier, "Cardiac biomarkers in haemodialysis patients: the prognostic value of amino-terminal pro-B-type natriuretic peptide and cardiac troponin T, " Nephron-Clinical Practice, vol. 107, no. 3, pp. c77-c81, 2007.
28. M. C. Iliou, C. Fumeron, M. O. Benoit et al. , "Factors associated with increased serum levels of cardiac troponins T and I in chronic haemodialysis patients: chronic haemodialysis and new cardiac markers evaluation (CHANCE) study, " Nephrology Dialysis Transplantation, vol. 16, no. 7, pp. 1452-1458, 2001.
29. F. Mallamaci, C. Zoccali, S. Parlongo et al. , "Troponin is related to left ventricular mass and predicts all-cause and cardiovascularmortality in hemodialysis patients, " The American Journal of Kidney Diseases, vol. 40, no. 1, pp. 68-75, 2002.
30. B. Havekes, J. G. van Manen, R. T. Krediet, E. W. Boeschoten, J. P. Vandenbroucke, and F. W. Dekker, "Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients, " American Journal of Kidney Diseases, vol. 47, no. 5, pp. 823-829, 2006.
31. T. Hayashi, Y. Obi, T. Kimura et al. , "Cardiac troponin T predicts occult coronary artery stenosis in patients with chronic kidney disease at the start of renal replacement therapy, " Nephrology Dialysis Transplantation, vol. 23, no. 9, pp. 2936-2942, 2008.
32. J. Dierkes, U. Domröse, S. Westphal et al. , "Cardiac troponin T predicts mortality in patients with end-stage renal disease, " Circulation, vol. 102, no. 16, pp. 1964-1969, 2000.
33. M. Goicoechea, S. Garcá De Vinuesa, F. Gómez-Campderá et al. , "Clinical significance of cardiac troponin T levels in chronic kidney disease patients: predictive value for cardiovascular risk, " American Journal of Kidney Diseases, vol. 43, no. 5, pp. 846-853, 2004.
34. C. DeFilippi, S. Wasserman, S. Rosanio et al. , "Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis, " The Journal of the American Medical Association, vol. 290, no. 3, pp. 353-359, 2003.
35. C. Melloni, K. P. Alexander, S. Milford-Beland et al. , "Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease, " Clinical Cardiology, vol. 31, no. 3, pp. 125-129, 2008.
36. A. X. Garg, P. G. Blake, W. F. Clark, C. M. Clase, R. B. Haynes, and L. M. Moist, "Association between renal insufficiency and malnutrition in older adults: results from the NHANES III, " Kidney International, vol. 60, no. 5, pp. 1867-1874, 2001.
37. M. G. Shlipak, L. F. Fried, C. Crump et al. , "Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency, " Circulation, vol. 107, no. 1, pp. 87-92, 2003.
38. H.-J. Hsu, C.-H. Yen, K.-H. Hsu et al. , "Chronic kidney disease stage is a modulator on the association between highsensitivity C-reactive protein and coronary vasospastic angina, " The Scientific World Journal, vol. 2014, Article ID 852507, 9 pages, 2014.
39. P. M. Ridker, "Clinical application of C-reactive protein for cardiovascular disease detection and prevention, " Circulation, vol. 107, no. 3, pp. 363-369, 2003.
40. T. A. Pearson, G. A. Mensah, R. W. Alexander et al. , "Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the AmericanHeart Association, " Circulation, vol. 107, no. 3, pp. 499-511, 2003.
41. F. M. van der Sande, J. P. Kooman, and K. M. Leunissen, "The predictive value of C-reactive protein in end-stage renal disease: is it clinically significant" Blood Purification, vol. 24, no. 4, pp. 335-341, 2006.
42. F. Mallamaci, G. Tripepi, S. Cutrupi, L. S. Malatino, and C. Zoccali, "Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, andmyocardiopathy in patients with ESRD, " Kidney International, vol. 67, no. 6, pp. 2330-2337, 2005.
43. S. Snaedal, O. Heimbürger, A. R. Qureshi et al. , "Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival, " American Journal of Kidney Diseases, vol. 53, no. 6, pp. 1024-1033, 2009.
44. M. M. Nascimento, R. Pecoits-Filho, A. R. Qureshi et al. , "The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study, " NephrologyDialysis Transplantation, vol. 19, no. 11, pp. 2803-2809, 2004.
45. S.-H. Liu, Y.-J. Li, H.-H. Wu et al. , "High-sensitivity C-reactive protein predicts mortality and technique failure in peritoneal dialysis patients, " PLoS ONE, vol. 9, no. 3, Article ID e93063, 2014.
46. M. Kanwar, M. Hashem, H. Rosman et al. , "Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients, " The American Journal of Cardiology, vol. 98, no. 9, pp. 1283-1287, 2006.
47. H. Honda, A. R. Qureshi, O. Heimbürger et al. , "Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, andmortality in patients with ESRD, " The American Journal of Kidney Diseases, vol. 47, no. 1, pp. 139-148, 2006.
48. C. Zoccali, G. Tripepi, and F. Mallamaci, "Predictors of cardiovascular death in ESRD, " Seminars in Nephrology, vol. 25, no. 6, pp. 358-362, 2005.
49. F. M. Fisher, M. E. Trujillo, W. Hanif et al. , "Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males, " Diabetologia, vol. 48, no. 6, pp. 1084-1087, 2005.
50. M. Bouskila, U. B. Pajvani, and P. E. Scherer, "Adiponectin: a relevant player in PPAR-agonist-mediated improvements in hepatic insulin sensitivity" International Journal ofObesity, vol. 29, supplement 1, pp. S17-S23, 2005.
51. T. Yokota, C. S. R. Meka, T. Kouro et al. , "Adiponectin, a fat cell product, influences the earliest lymphocyte precursors in bone marrow cultures by activation of the cyclooxygenaseprostaglandin pathway in stromal cells, " The Journal of Immunology, vol. 171, no. 10, pp. 5091-5099, 2003.
52. M. C. Wulster-Radcliffe, K. M. Ajuwon, J. Wang, J. A. Christian, and M. E. Spurlock, "Adiponectin differentially regulates cytokines in porcine macrophages, " Biochemical and Biophysical Research Communications, vol. 316, no. 3, pp. 924-929, 2004.
53. K. Hotta, T. Funahashi, Y. Arita et al. , "Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 6, pp. 1595-1599, 2000.
54. J. P. Whitehead, A. A. Richards, I. J. Hickman, G. A. Macdonald, and J. B. Prins, "Adiponectin-a key adipokine in the metabolic syndrome, " Diabetes, Obesity and Metabolism, vol. 8, no. 3, pp. 264-280, 2006.
55. Z. Dzielínska, A. Januszewicz, A. Wicek et al. , "Decreased plasma concentration of a novel anti-inflammatory protein-adiponectin-in hypertensive men with coronary artery disease, " Thrombosis Research, vol. 110, no. 5-6, pp. 365-369, 2003.
56. N. Komura, S. Kihara, M. Sonoda et al. , "Increment and impairment of adiponectin in renal failure, " Cardiovascular Research, vol. 86, no. 3, pp. 471-477, 2010.
57. M. Kumada, S. Kihara, S. Sumitsuji et al. , "Association of hypoadiponectinemia with coronary artery disease in men, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 85-89, 2003.
58. N. Ouchi, M. Ohishi, S. Kihara et al. , "Association of hypoadiponectinemia with impaired vasoreactivity, " Hypertension, vol. 42, no. 3, pp. 231-234, 2003.
59. B. Kollerits, D. Fliser, I. M. Heid, E. Ritz, and F. Kronenberg, "Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease study, " Kidney International, vol. 71, no. 12, pp. 1279-1286, 2007.
60. C. Zoccali and F. Mallamaci, "Adiponectin and leptin in chronic kidney disease: causal factors or mere risk markers" Journal of Renal Nutrition, vol. 21, no. 1, pp. 87-91, 2011.
61. B. Becker, F. Kronenberg, J. T. Kielstein et al. , "Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study, " Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 1091-1098, 2005.
62. C. Zoccali, F. Mallamaci, G. Tripepi et al. , "Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease, " Journal of the American Society of Nephrology, vol. 13, no. 1, pp. 134-141, 2002.
63. V. Menon, L. Li, X. Wang et al. , "Adiponectin and mortality in patients with chronic kidney disease, " Journal of the American Society of Nephrology, vol. 17, no. 9, pp. 2599-2606, 2006.
64. O. M. Kaisar, D. W. Johnson, J. B. Prins, andN. Isbel, "The role of novel biomarkers of cardiovascular disease in chronic kidney disease: focus on adiponectin and leptin, " Current Cardiology Reviews, vol. 4, no. 4, pp. 287-292, 2008.
65. P. Stenvinkel, "Leptin-a new hormone of definite interest for the nephrologist, " Nephrology Dialysis Transplantation, vol. 13, no. 5, pp. 1099-1101, 1998.
66. S. K. Fried, M. R. Ricci, C. D. Russell, and B. Laferrère, "Regulation of leptin production in humans, " Journal of Nutrition, vol. 130, no. 12, pp. 3127-3131S, 2000.
67. R. V. Considine, M. K. Sinha, M. L. Heiman et al. , "Serum immunoreactive-leptin concentrations in normal-weight and obese humans, "The New England Journal of Medicine, vol. 334, no. 5, pp. 292-295, 1996.
68. D. G. Baskin, J. E. Blevins, and M. W. Schwartz, "How the brain regulates food intake and body weight: the role of leptin, " Journal of Pediatric Endocrinology and Metabolism, vol. 14, no. 6, pp. 1417-1429, 2001.
69. T. M. Mizuno, S. P. Kleopoulos, H. T. Bergen, J. L. Roberts, C. A. Priest, and C. V. Mobbs, "Hypothalamic pro-opiomelanocortin mRNAis reduced by fasting and [corrected] in ob/ob and db/db mice, but is stimulated by leptin, " Diabetes, vol. 47, no. 2, pp. 294-297, 1998.
70. M. Mapfei, J. Halaas, E. Ravussin et al. , "Leptin levels in human and rodent: measurement of plasma leptin and obRNAin obese and weight-reduced subjects, " Nature Medicine, vol. 1, no. 11, pp. 1155-1161, 1995.
71. G. Boden, K. Sargrad, C. Homko, M. Mozzoli, and T. P. Stein, "Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes, " Annals of Internal Medicine, vol. 142, no. 6, pp. 403-411, 2005.
72. E. Merabet, S. Dagogo-Jack, D. W. Coyne et al. , "Increased plasma leptin concentration in end-stage renal disease, " Journal of Clinical Endocrinology andMetabolism, vol. 82, no. 3, pp. 847-850, 1997. Disease Markers 13
73. J. J. Déz, P. Iglesias, M. J. Fernández-Reyes et al. , "Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with endstage renal disease, " Clinical Endocrinology, vol. 62, no. 2, pp. 242-249, 2005.
74. D. Teta, A. Bevington, J. Brown, I. Pawluczyk, K. Harris, and J. Walls, "Acidosis downregulates leptin production from cultured adipocytes through a glucose transport-dependent posttranscriptional mechanism, " Journal of the American Society of Nephrology, vol. 14, no. 9, pp. 2248-2254, 2003.
75. L. Nordfors, F. Lönnqvist, O. Heimbürger, A. Danielsson, M. Schalling, and P. Stenvinkel, "Low leptin gene expression and hyperleptinemia in chronic renal failure, " Kidney International, vol. 54, no. 4, pp. 1267-1275, 1998.
76. A. Scholze and M. Tepel, "Role of leptin in reverse epidemiology in chronic kidney disease, " Seminars in Dialysis, vol. 20, no. 6, pp. 534-538, 2007.
77. M. Ciccone, R. Vettor, N. Pannacciulli et al. , "Plasma leptin is independently associated with the intima-media thickness of the common carotid artery, " International Journal of Obesity, vol. 25, no. 6, pp. 805-810, 2001.
78. A. Singhal, I. S. Farooqi, T. J. Cole et al. , "Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease" Circulation, vol. 106, no. 15, pp. 1919-1924, 2002.
79. M. C. Lee, Y. C. Chen, G. J. Ho, M. H. Shih, K. C. Chou, and B. G. Hsu, "Serum leptin levels positively correlate with peripheral arterial stiffness in kidney transplantation patients, " Transplantation Proceedings, vol. 46, no. 2, pp. 353-358, 2014.
80. A. Aguilera, M. A. Bajo, F. Rebollo et al. , "Leptin as a marker of nutrition and cardiovascular risk in peritoneal dialysis patients, " Advances in Peritoneal Dialysis, vol. 18, pp. 212-217, 2002.
81. A. Scholze, D. Rattensperger, W. Zidek, and M. Tepel, "Low serum leptin predicts mortality in patients with chronic kidney disease stage 5, " Obesity, vol. 15, no. 6, pp. 1617-1622, 2007.
82. I. Beberashvili, I. Sinuani, A. Azar et al. , "Longitudinal study of leptin levels in chronic hemodialysis patients, " Nutrition Journal, vol. 10, no. 1, article 68, 2011.
83. Y.-C. Tsai, C.-T. Lee, T.-L. Huang et al. , "Inflammatory marker but not adipokine predicts mortality among long-term hemodialysis patients, " Mediators of Inflammation, vol. 2007, Article ID 19891, 5 pages, 2007.
84. S. Moe, T. Drueke, G. Block, and J. Cannata-andia, "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD), " Kidney International, vol. 113, pp. S1-S130, 2009.
85. S. Liu, J. Zhou, W. Tang, X. Jiang, D. W. Rowe, and L. D. Quarles, "Pathogenic role of Fgf23 in Hyp mice, " The American Journal of Physiology-Endocrinology andMetabolism, vol. 291, no. 1, pp. E38-E49, 2006.
86. H. Segawa, E. Kawakami, I. Kaneko et al. , "Effect of hydrolysisresistant FGF23-R179Q on dietary phosphate regulation of the renal type-IINa/Pi transporter, " Pflugers Archiv, vol. 446, no. 5, pp. 585-592, 2003.
87. T. Shimada, H. Hasegawa, Y. Yamazaki et al. , "FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis, " Journal of Bone and Mineral Research, vol. 19, no. 3, pp. 429-435, 2004.
88. M. Yamazaki, K. Ozono, T. Okada et al. , "Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells, " Journal of Cellular Biochemistry, vol. 111, no. 5, pp. 1210-1221, 2010.
89. V. P. Eswarakumar, I. Lax, and J. Schlessinger, "Cellular signaling by fibroblast growth factor receptors, " Cytokine and Growth Factor Reviews, vol. 16, no. 2, pp. 139-149, 2005.
90. M. Kuro-O, "Phosphate and klotho, " Kidney International, vol. 79, supplement 121, pp. S20-S23, 2011.
91. M. Christov, S. S. Waikar, R. C. Pereira et al. , "Plasma FGF23 levels increase rapidly after acute kidney injury, " Kidney International, vol. 84, no. 4, pp. 776-785, 2013.
92. O. M. Gutiérrez, M. Mannstadt, T. Isakova et al. , "Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis, " The New England Journal of Medicine, vol. 359, no. 6, pp. 584-592, 2008.
93. J. H. Ix, M. G. Shlipak, C. L. Wassel, and M. A. Whooley, "Fibroblast growth factor-23 and early decrements in kidney function: the heart and soul study, " Nephrology Dialysis Transplantation, vol. 25, no. 3, pp. 993-997, 2010.
94. M. Kanbay, M. Nicoleta, Y. Selcoki et al. , "Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease, " Clinical Journal of the American Society of Nephrology, vol. 5, no. 10, pp. 1780-1786, 2010.
95. S. Seiler, B. Reichart, D. Roth, E. Seibert, D. Fliser, and G. H. Heine, "FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment, " Nephrology Dialysis Transplantation, vol. 25, no. 12, pp. 3983-3989, 2010.
96. T. Isakova, P. Wahl, G. S. Vargas et al. , "Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease, " Kidney International, vol. 79, no. 12, pp. 1370-1378, 2011.
97. J. J. Scialla, H. Xie, M. Rahman et al. , "Fibroblast growth factor-23 and cardiovascular events in CKD, " Journal of the American Society of Nephrology, vol. 25, no. 2, pp. 349-360, 2014.
98. C. M. Rebholz, M. E. Grams, J. Coresh et al. , "Serum fibroblast growth factor-23 is associated with incident kidney disease, " Journal of the American Society of Nephrology, vol. 26, no. 1, pp. 192-200, 2015.
99. B. D. Parker, L. J. Schurgers, V. M. Brandenburg et al. , "The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the heart and soul study, " Annals of Internal Medicine, vol. 152, no. 10, pp. 640-648, 2010.
100. H. J. Oh, B. Y. Nam, M. J. Lee et al. , "Decreased circulating Klotho levels in patients undergoing dialysis and relationship to oxidative stress and inflammation, " Peritoneal Dialysis International, vol. 35, no. 1, pp. 43-51, 2015.
101. R. D. Semba, A. R. Cappola, K. Sun et al. , "Plasma klotho and mortality risk in older community-dwelling adults, " Journals of Gerontology-Series A Biological Sciences and Medical Sciences, vol. 66, no. 7, pp. 794-800, 2011.
102. D. E. Arking, D. M. Becker, L. R. Yanek et al. , "KLOTHO allele status and the risk of early-onset occult coronary artery disease, " TheAmerican Journal ofHumanGenetics, vol. 72, no. 5, pp. 1154-1161, 2003.
103. J. F. Navarro-González, J. Donate-Correa, M. M. de Fuentes, H. Pérez-Hernández, R. Martinez-Sanz, and C. Mora-Fernández, "Reduced Klotho is associated with the presence and severity of coronary artery disease, " Heart, vol. 100, no. 1, pp. 34-40, 2014.
104. I. Agarwal, N. Ide, J. H. Ix et al. , "Fibroblastgrowthfactor-23 and cardiac structure and function, " Journal of the American Heart Association, vol. 3, no. 1, Article ID e000584, 2014.
105. M. Kuro-o, "Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism, " Nature Reviews Nephrology, vol. 9, no. 11, pp. 650-660, 2013.
106. A. Pasch, S. Farese, S. Gräber et al. , "Nanoparticle-based test measures overall propensity for calcification in serum, " Journal of the American Society of Nephrology, vol. 23, no. 10, pp. 1744-1752, 2012.
107. E. R. Smith, M. L. Ford, L. A. Tomlinson, C. Rajkumar, L. P. McMahon, and S. G. Holt, "Phosphorylated fetuin-Acontaining calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD, " Nephrology, Dialysis, Transplantation, vol. 27, no. 5, pp. 1957-1966, 2012.
108. E. R. Smith, E. Hanssen, L. P. McMahon, and S. G. Holt, "Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage, " PLoS ONE, vol. 8, no. 4, Article ID e60904, 2013.
109. E. R. Smith, M. L. Ford, L. A. Tomlinson et al. , "Serumcalcification propensity predicts all-causemortality in predialysisCKD, " Journal of theAmerican Society of Nephrology, vol. 25, no. 2, pp. 339-348, 2014.
110. M. G. Vervloet, Z. A. Massy, V. M. Brandenburg et al. , "Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders, " The Lancet Diabetes and Endocrinology, vol. 2, no. 5, pp. 427-436, 2014.
111. V. M. Brandenburg, R. Kramann, R. Koos et al. , "Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study, " BMC Nephrology, vol. 14, no. 1, article 219, 2013.
112. R. Kramann, V. M. Brandenburg, L. J. Schurgers et al. , "Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy, " NephrologyDialysis Transplantation, vol. 28, no. 4, pp. 856-868, 2013.
113. D. Cejka, J. Herberth, A. J. Branscum et al. , "Sclerostin and dickkopf-1 in renal osteodystrophy, " Clinical Journal of the American Society of Nephrology, vol. 6, no. 4, pp. 877-882, 2011.
114. S. Thambiah, R. Roplekar, P. Manghat et al. , "Circulating sclerostin and dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness, " Calcified Tissue International, vol. 90, no. 6, pp. 473-480, 2012.
115. L. Desjardins, S. Liabeuf, R. B. Oliveira et al. , "Uremic toxicity and sclerostin in chronic kidney disease patients, " Néphrologie &Thérapeutique, vol. 10, no. 6, pp. 463-470, 2014.
116. L. Viaene, G. J. Behets, K. Claes et al. , "Sclerostin: another bonerelated protein related to all-causemortality in haemodialysis" Nephrology Dialysis Transplantation, vol. 28, no. 12, pp. 3024-3030, 2013.
117. C. Drechsler, P. Evenepoel, M. G. Vervloet et al. , "High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study, " Nephrology Dialysis Transplantation, vol. 30, no. 2, pp. 288-293, 2015.
118. K. Mori, H. T. Lee, D. Rapoport et al. , "Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury, " The Journal of Clinical Investigation, vol. 115, no. 3, pp. 610-621, 2005.
119. K. Mori and K. Nakao, "Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage, " Kidney International, vol. 71, no. 10, pp. 967-970, 2007.
120. K. M. Schmidt-Ott, K. Mori, Y. L. Jau et al. , "Dual action of neutrophil gelatinase-associated lipocalin, " Journal of the American Society of Nephrology, vol. 18, no. 2, pp. 407-413, 2007.
121. R. Hirsch, C. Dent, H. Pfriem et al. , "NGAL is an early predictive biomarker of contrast-induced nephropathy in children, " Pediatric Nephrology, vol. 22, no. 12, pp. 2089-2095, 2007.
122. L. Kjeldsen, A. H. Johnsen, H. Sengelov, and N. Borregaard, "Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase, " The Journal of Biological Chemistry, vol. 268, no. 14, pp. 10425-10432, 1993.
123. J. B. Cowland and N. Borregaard, "Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans, " Genomics, vol. 45, no. 1, pp. 17-23, 1997.
124. A. Friedl, S. P. Stoesz, P. Buckley, and M. N. Gould, "Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression, " Histochemical Journal, vol. 31, no. 7, pp. 433-441, 1999.
125. A.-L. Hemdahl, A. Gabrielsen, C. Zhu et al. , "Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 1, pp. 136-142, 2006.
126. J. R. Charlton, D. Portilla, and M. D. Okusa, "A basic science view of acute kidney injury biomarkers, " Nephrology Dialysis Transplantation, vol. 29, no. 7, pp. 1301-1311, 2014.
127. C. Donadio, "Effect of glomerular filtration rate impairment on diagnostic performance of neutrophil gelatinase-associated lipocalin and B-type natriuretic peptide as markers of acute cardiac and renal failure in chronic kidney disease patients, " Critical Care, vol. 18, no. 1, article R39, 2014.
128. J. Mishra, M. A. Qing, A. Prada et al. , "Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury, " Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2534-2543, 2003.
129. M. Haase, R. Bellomo, P. Devarajan, P. Schlattmann, and A. Haase-Fielitz, "Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis, " The American Journal of Kidney Diseases, vol. 54, no. 6, pp. 1012-1024, 2009.
130. J. Mishra, C. Dent, R. Tarabishi et al. , "Neutrophil gelatinaseassociated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery, " The Lancet, vol. 365, no. 9466, pp. 1231-1238, 2005.
131. T. L. Nickolas, M. J. O'Rourke, J. Yang et al. , "Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury, " Annals of Internal Medicine, vol. 148, no. 11, pp. 810-819, 2008.
132. A. Viau, K. El Karoui, D. Laouari et al. , "Lipocalin 2 is essential for chronic kidney disease progression in mice and humans, " Journal of Clinical Investigation, vol. 120, no. 11, pp. 4065-4076, 2010.
133. D. Bolignano, A. Lacquaniti, G. Coppolino et al. , "Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients, " Kidney and Blood Pressure Research, vol. 32, no. 2, pp. 91-98, 2009.
134. K. D. Liu, W. Yang, A. H. Anderson et al. , "Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease, " Kidney International, vol. 83, no. 5, pp. 909-914, 2013.
135. F. Furuya, H. Shimura, H. Yokomichi et al. , "Neutrophil gelatinase-associated lipocalin levels associated with cardiovascular disease in chronic kidney disease patients, " Clinical and Experimental Nephrology, vol. 18, no. 5, pp. 778-783, 2014.
136. A. S. Maisel, C. Mueller, R. Fitzgerald et al. , "Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with BtypeNaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial, " European Journal of Heart Failure, vol. 13, no. 8, pp. 846-851, 2011.
137. A. Thompson, P. Gao, L. Orfei et al. , "Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies, " The Lancet, vol. 375, no. 9725, pp. 1536-1544, 2010.
138. M. R. Bootcov, A. R. Bauskin, S. M. Valenzuela et al. , "MIC-1, a novel macrophage inhibitory cytokine, is a divergentmember of the TGF-superfamily, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 21, pp. 11514-11519, 1997.
139. T. Kempf, M. Eden, J. Strelau et al. , "The transforming growth factor-superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury, " Circulation Research, vol. 98, no. 3, pp. 351-360, 2006.
140. J. Strelau, M. Böttner, P. Lingor et al. , "GDF-15/MIC-1 a novel member of the TGF-beta superfamily, " Journal of Neural Transmission, Supplementum, no. 60, pp. 273-276, 2000.
141. J. Xu, T. R. Kimball, J. N. Lorenz et al. , "GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation, " Circulation Research, vol. 98, no. 3, pp. 342-350, 2006.
142. D. Schlittenhardt, A. Schober, J. Strelau et al. , "Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions, " Cell and Tissue Research, vol. 318, no. 2, pp. 325-333, 2004.
143. D. A. Brown, S. N. Breit, J. Buring et al. , "Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study, " The Lancet, vol. 359, no. 9324, pp. 2159-2163, 2002.
144. T. Kempf, E. Björklund, S. Olofsson et al. , "Growthdifferentiation factor-15 improves risk stratification in STsegment elevation myocardial infarction, " European Heart Journal, vol. 28, no. 23, pp. 2858-2865, 2007.
145. J. E. Ho, S.-J. Hwang, K. C. Wollert et al. , "Biomarkers of cardiovascular stress and incident chronic kidney disease, " Clinical Chemistry, vol. 59, no. 11, pp. 1613-1620, 2013.
146. M. Lajer, A. Jorsal, L. Tarnow, H.-H. Parving, and P. Rossing, "Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascularmortality aswell as deterioration of kidney function in type 1 diabetic patients with nephropathy, " Diabetes Care, vol. 33, no. 7, pp. 1567-1572, 2010.
147. L. Wallentin, B. Zethelius, L. Berglund et al. , "GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men, " PLoS ONE, vol. 8, no. 12, Article ID e78797, 2013.
148. M. T. Bedford and S. G. Clarke, "Protein arginine methylation in mammals: who, what, and why, "Molecular Cell, vol. 33, no. 1, pp. 1-13, 2009.
149. R. H. Böger, R. Maas, F. Schulze, and E. Schwedhelm, "Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk, " Pharmacological Research, vol. 60, no. 6, pp. 481-487, 2009.
150. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada, "Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure, " The Lancet, vol. 339, no. 8793, pp. 572-575, 1992.
151. P. Schwarz, R. Diem, N. J. Dun, and U. Forstermann, "Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves, " Circulation Research, vol. 77, no. 4, pp. 841-848, 1995.
152. F. Costa, N. J. Christensen, G. Farley, and I. Biaggioni, "NO modulates norepinephrine release in human skeletal muscle: implications for neural preconditioning, " American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 280, no. 5, pp. R1494-R1498, 2001.
153. M. L. Hijmering, E. S. G. Stroes, J. Olijhoek, B. A. Hutten, P. J. Blankestijn, and T. J. Rabelink, "Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation, " Journal of the American College of Cardiology, vol. 39, no. 4, pp. 683-688, 2002.
154. F. Mallamaci, G. Tripepi, R. Maas, L. Malatino, R. Böger, and C. Zoccali, "Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease, " Journal of the American Society of Nephrology, vol. 15, no. 2, pp. 435-441, 2004.
155. C. Zoccali, S. M. Bode-Böger, F. Mallamaci et al. , "Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study, " The Lancet, vol. 358, no. 9299, pp. 2113-2117, 2001.
156. F. Mallamaci, F. Benedetto, G. Tripepi, L. Malatino, R. Boeger, and C. Zoccali, "Asymmetric dimethylarginine (ADMA) and carotid atherosclerosis in end-stage renal disease, " Journal of Hypertension, vol. 20, p. S140, 2002.
157. F. Mallamaci, G. Tripepi, G. Bonanno, G. Seminara, P. Fatuzzo, and F. Rapisarda, "Asymmetric dimethylarginine (ADMA), left ventricular hypertrophy and systolic dysfunction in hemodialysis patients, " Journal of the American Society of Nephrology, vol. 13, 2002.
158. D. Fliser, F. Kronenberg, J. T. Kielstein et al. , "Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study, " Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2456-2461, 2005.
159. M. Busch, C. Fleck, G. Wolf, and G. Stein, "Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease-possible candidates for paradoxical epidemiology" Amino Acids, vol. 30, no. 3, pp. 225-232, 2006.
160. P. N. Durrington, B. Mackness, and M. I. Mackness, "Paraoxonase and atherosclerosis, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 4, pp. 473-480, 2001.
161. D. Juretíc, M. Tadijanovíc, B. Rekíc, V. Simeon-Rudolf, E. Reiner, and M. Baricíc, "Serum paraoxonase activities in hemodialyzed uremic patients: cohort study, " Croatian Medical Journal, vol. 42, no. 2, pp. 146-150, 2001.
162. M. Dirican, R. Akcą, E. Sarandöl, and K. Dilek, "Serum paraoxonase activity in uremic predialysis and hemodialysis patients, " Journal of Nephrology, vol. 17, no. 6, pp. 813-818, 2004.
163. S. A. Saeed, M. Elsharkawy, K. Elsaeed, and O. Fooda, "Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients, " Hemodialysis International, vol. 12, no. 4, pp. 471-479, 2008.
164. F. Sztanek, I. Seres, M. Harangi et al. , "Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. Anovel cardiovascular biomarker in end-stage renal disease, " Nephrology Dialysis Transplantation, vol. 27, no. 7, pp. 2866-2872, 2012.
165. A. Gugliucci, E. Kinugasa, H. Ogata, R. Caccavello, and S. Kimura, "Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL, " Clinica Chimica Acta, vol. 430, pp. 9-14, 2014.